Tempest Therapeutics, Inc. (TPST)
Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
|
Dr. Matthew Angel Ph.D.
|
President, CEO & Chair of the Board | -- | -- | 1981 |
|
Ms. Stephanie Horn-Warnock
|
CFO, Principal Financial and Accounting Officer, Treasurer & Corporate Secretary | -- | -- | 1989 |
|
Dr. Andrew Fang Ph.D.
|
Head of Business Development | -- | -- | -- |
Tempest Therapeutics, Inc.
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 4
Description
Tempest Therapeutics, Inc., a clinical-stage biotechnology company, develops small molecule therapeutics to treat cancer. Its lead product candidates include Amezalpat, an oral small molecule selective antagonist of peroxisome proliferator-activated receptor alpha for the treatment of first-line unresectable or metastatic hepatocellular carcinoma that completed Phase 2 clinical trial; and TPST-1495, a small-molecule dual antagonist of the EP2 and EP4 receptors of prostaglandin E2 for treating various cancers. The company has a collaboration agreement with F. Hoffmann-La Roche Ltd. for the development of Amezalpat into a global first-line randomized study; and has a product development and investigator-initiated trial collaboration agreement with Heibei Senlang Biotechnology Co., Ltd. to develop TPST-4003 product candidate. Tempest Therapeutics, Inc. is headquartered in Brisbane, California.
Corporate Governance
Upcoming Events
November 9, 2026 at 9:00 PM UTC
Tempest Therapeutics, Inc. Earnings Date
